FDA Suspends Ban on Juul E-cigarette Sales

Jul.13.2022
FDA Suspends Ban on Juul E-cigarette Sales
The FDA temporarily suspends ban on Juul sales for extra review, but concerns over health risks persist.

The US Food and Drug Administration (FDA) has suspended its ban on the sale of Juul Labs' e-cigarettes, stating that additional scrutiny is required for the company's marketing application. Following Juul's appeal for an urgent review of the FDA's order, the federal appeals court decided to temporarily freeze the FDA's ban a few weeks ago.


However, this once flourishing company still remains in a difficult situation: the US Food and Drug Administration has only temporarily halted the re-evaluation ban, it has not been lifted.


Juul has been in the limelight in part due to its prominent position in the e-cigarette industry. However, as the company faces potential extinction, it may become the first casualty while the rest of the e-cigarette industry comes under increasing government scrutiny.


Dr. Zubair Karim, an assistant professor in the Department of Interdisciplinary Health Sciences at Augusta University, conducted research on Juul e-cigarettes and their potential to increase the risk of blood clots and other complications in users.


According to Karim, thrombosis is the partial or complete blockage of blood vessels, whether it occurs in veins or arteries, which restricts the natural flow of blood.


According to the location of blood clot formation, there are several potential complications. The most severe issues include stroke, heart attack, and a serious respiratory condition known as pulmonary embolism. Without prompt treatment, these conditions can be life-threatening. However, by focusing on lifestyle changes such as increasing physical activity, quitting smoking, losing weight, maintaining a balanced diet, avoiding junk food, and managing other health conditions, it is possible to prevent the disease from advancing.


As a ban on Juul products looms, it could lead to a ban on other companies' electronic cigarette products.


Karim stated, "This is the first step in banning e-cigarettes, and the FDA has taken an important and bold move.


Gradually, this will pave the way for the banning of other e-cigarette products. Juul and other products are no different, but Juul is becoming increasingly popular among our younger generation. Many localities and states have recently begun implementing laws banning the use of e-cigarettes, although some states with comprehensive smoke-free laws will still allow the use of e-cigarettes in bars and restaurants while prohibiting their use in other indoor venues.


For years, electronic cigarettes and their devices have been considered a "safer" alternative to traditional cigarettes, but their flavors and packaging have attracted children, and there are renewed efforts to study their possible side effects.


Looking at the long-term effects, both smoking and vaping have similar side effects and pose serious health risks. Scientists do not fully understand the long-term impact of vaping on health, but studies show that electronic cigarettes are not a safe alternative to smoking," said Karim.


In recent years, it has been observed that electronic cigarettes are becoming increasingly popular among young people. Additionally, electronic cigarettes contain high doses of nicotine, which is known to slow the development of fetuses, children, and adolescents' brains. Furthermore, electronic cigarettes involve inhaling aerosols that contain multiple chemicals, including those used for flavoring via electronic cigarettes or other devices. Additionally, the liquid produced in electronic cigarettes can be hazardous if swallowed, inhaled, or applied topically to the skin for both adults and children.


Despite this, e-cigarettes still contain harmful chemicals such as diacetyl, carcinogens, heavy metals, volatile organic compounds, and toxic chemicals not found in traditional cigarettes. In summary, the long-term toxic effects of e-cigarette use on overall health are similar to those of traditional cigarettes.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Major U.S.  Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
Major U.S. Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
New York vape distributor Ecto World, which operates as Demand Vape, hired political consultant Roger Stone to lobby the Executive Office of the President on regulation of vaping and related products while facing state enforcement and multiple lawsuits. Public lobbying disclosures show that Ecto World paid at least $300,000 for the work through June 30, 2026. Separately, New York State announced in March that more than 28,500 pounds of vaping products tied to the company had been seized, while New York City and the state have pursued legal or enforcement actions. Public records do not show that the lobbying directly changed any specific regulatory or enforcement outcome.
Sep.08
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
According to Free Malaysia Today on August 26, 2026, Malaysia’s Health Minister Dzulkefly Ahmad said the Health Ministry would explain the government’s decision to withdraw its appeal against a High Court ruling involving the exemption of liquid nicotine used in vape products from the Poisons List. The High Court previously ruled that the exemption decision was irrational. Dzulkefly said withdrawing the appeal did not mean the government would stop regulating vaping, and that future regulatory approaches would continue under existing legal frameworks.
Aug.28
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07